P476 Combined therapy with adalimumab and mesenchymal stromal cells contributes to reduction in the degree of inflammation in ulcerative colitis
O. Knyazev1, A. Kagramanova1, D. Kulakov*1, M. Zvyaglova1, A. Parfenov1
1Moscow Clinical Scientific Center named after A. S. Loginov, Department of inflammatory bowel diseases, Moscow, Russian Federation
One of the new promising methods of treatment of patients with ulcerative colitis (UC) is biological therapy using bone marrow mesenchymal stromal cells (MSC). In some cases, simultaneously with MSC, patients receive concomitant anticytokine therapy. Currently, a new strategy for UC therapy is to achieve a deep remission of the disease. To compare the level of immunobiological and histological markers of inflammation—C-reactive protein (CRP), the Geboes Score (GS) and faecal calprotectin (FCP)—in patients with UC receiving cell therapy MSC, anti-cytokine therapy with adalimumab (ADA), and combined therapy of bone marrow MSC and ADA.
Sixty patients with total ulcerative colitis of moderate severity were divided into groups depending on the therapy. The first group of patients with UC aged from 19 to 56 years (Me-29) (
After 26 weeks from the start of therapy in the first group of patients, the level of CPP was 6.8 ± 1.1 mg/l, in the second group 7.4 ± 1.3 mg/l, in the third group 7.9 ± 1.0 mg/l (
Combined mesenchymal stromal cells and anti-cytokine therapy with adalimumab contributes to a more pronounced reduction in the degree of inflammation of the intestinal mucosa.